AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17116511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 15375469 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical valvular treatment associated with isolation of the left atrial posterior wall (treated group)
Number of subjects: 29
Study 15375469 — intervention group
Group type: COMPARATOR
Intervention: Surgical valvular treatment (control group)
Number of subjects: 29
Study 11719726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (600 mg)
Number of subjects: 12
Study 11719726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9127159 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (200 micrograms)
Number of subjects: 84
Study 9127159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 1337465 — intervention group
Group type: EXPERIMENTAL
Intervention: DPE (doxorubicin, cisplatin and etoposide)
Number of subjects: 60
Study 1337465 — intervention group
Group type: COMPARATOR
Intervention: CIV (carboplatin, ifosfamide and vincristine)
Number of subjects: 60
Study 1337465 — intervention group
Group type: EXPERIMENTAL
Intervention: DPE
Number of subjects: 60
Study 1337465 — intervention group
Group type: COMPARATOR
Intervention: CIV
Number of subjects: 60
Study 3927932 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (Eldepryl)
Number of subjects: 12
Study 3927932 — intervention group
Group type: COMPARATOR
Intervention: Fenetylline
Number of subjects: 12
Study 3927932 — intervention group
Group type: COMPARATOR
Intervention: Chlorphenoxamine
Number of subjects: 12
Study 3927932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31393354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 48
Study 31393354 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 48
Study 29133014 — intervention group
Group type: EXPERIMENTAL
Intervention: BrECAPP (brentuximab vedotin 1.8 mg/kg on day 1, etoposide 200 mg/m2 on days 2-4, doxorubicin 35 mg/m2 on day 2, cyclophosphamide 1250 mg/m2 on day 2, procarbazine 100 mg/m2 on days 2-8, and prednisone 40 mg/m2 on days 2-15)
Number of subjects: 104
Study 29133014 — intervention group
Group type: COMPARATOR
Intervention: BrECADD (brentuximab vedotin 1.8 mg/kg on day 1, etoposide 150 mg/m2 on days 2-4, doxorubicin 40 mg/m2 on day 2, cyclophosphamide 1250 mg/m2 on day 2, dacarbazine 250 mg/m2 on days 3-4, and dexamethasone 40 mg on days 2-5)
Number of subjects: 104
Study 25415628 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose succinylcholine (0.5 mg/kg)
Number of subjects: 95
Study 25415628 — intervention group
Group type: COMPARATOR
Intervention: Low-dose rocuronium with sugammadex (0.25 mg/kg and 0.5 mg/kg respectively)
Number of subjects: 95
Study 23418822 — intervention group
Group type: EXPERIMENTAL
Intervention: New amino acid-based formula (Sineall, Humana, Milan, Italy)
Number of subjects: 60
Study 23418822 — intervention group
Group type: COMPARATOR
Intervention: Validated amino acid-based formula (placebo)
Number of subjects: 60
Study 21791080 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutorial
Number of subjects: 0
Study 21791080 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutorial + Practice Exercise
Number of subjects: 0
Study 21791080 — intervention group
Group type: COMPARATOR
Intervention: AGREE II User's Manual PDF (control condition)
Number of subjects: 0
Study 17913794 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (160 mg twice daily for 6 days)
Number of subjects: 16
Study 17913794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16927766 — intervention group
Group type: EXPERIMENTAL
Intervention: Short wavelength automated perimetry (SWAP)
Number of subjects: 55
Study 16927766 — intervention group
Group type: COMPARATOR
Intervention: Standard automated perimetry (SAP)
Number of subjects: 55
Study 12605721 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching pursuit algorithm for time-frequency analysis of EEG
Number of subjects: 0
Study 10781122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask tracheal tube
Number of subjects: 36
Study 10781122 — intervention group
Group type: COMPARATOR
Intervention: Standard tracheal tube
Number of subjects: 36
Study 8836757 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose diltiazem (1 mg)
Number of subjects: 38
Study 8836757 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose diltiazem (2 or 3 mg)
Number of subjects: 38
Study 8836757 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo (control group)
Number of subjects: 38
Study 1442572 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day of isosorbide dinitrate (ISDN)
Number of subjects: 18
Study 1442572 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day of isosorbide dinitrate (ISDN)
Number of subjects: 18
Study 1442572 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day of transdermal nitrate
Number of subjects: 18
Study 1442572 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day of transdermal nitrate
Number of subjects: 18
Study 1442572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3914178 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaprostil 10 micrograms
Number of subjects: 8
Study 3914178 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaprostil 25 micrograms
Number of subjects: 8
Study 3914178 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaprostil 50 micrograms
Number of subjects: 8
Study 3914178 — intervention group
Group type: COMPARATOR
Intervention: Control (0 micrograms)
Number of subjects: 8
Study 3524473 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ribavirin (14 infants)
Number of subjects: 26
Study 3524473 — intervention group
Group type: COMPARATOR
Intervention: Normal saline aerosol (12 infants)
Number of subjects: 26
Study 3524473 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ribavirin (20 infants with RSV identified)
Number of subjects: 26
Study 3524473 — intervention group
Group type: COMPARATOR
Intervention: Normal saline aerosol (20 infants with RSV identified)
Number of subjects: 26
Study 31851982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemodiafiltration (HDF)
Number of subjects: 197
Study 31851982 — intervention group
Group type: COMPARATOR
Intervention: High flux hemodialysis (HD)
Number of subjects: 197
Study 31851982 — intervention group
Group type: EXPERIMENTAL
Intervention: 1st shift dialysis
Number of subjects: 197
Study 30537951 — intervention group
Group type: EXPERIMENTAL
Intervention: AOI of 5 L/min oxygen on the non-ventilated lung immediately at the beginning of OLV
Number of subjects: 54
Study 30537951 — intervention group
Group type: COMPARATOR
Intervention: Traditional OLV mode
Number of subjects: 54
Study 28590362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 58
Study 28590362 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 58
Study 28590362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 24107257 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of a 3% clodronate solution mixed with Tween-20 at a 1:3 ratio
Number of subjects: 39
Study 24107257 — intervention group
Group type: COMPARATOR
Intervention: Conventional implant procedure (control side)
Number of subjects: 39
Study 24107257 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of a 3% clodronate solution
Number of subjects: 39
Study 24211360 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthful diet intervention with dietary advice aimed at meeting nutritional requirements
Number of subjects: 1250
Study 24211360 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1250
Study 21178592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 11
Study 21178592 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 11
Study 18326593 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate, high-saturated-fat weight-loss diet (LC)
Number of subjects: 99
Study 18326593 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric high-carbohydrate, low-saturated-fat diet (HC)
Number of subjects: 99
Study 16599649 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 202
Study 16599649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 14555365 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (enriched stimulus environment, collaborative multidisciplinary interventions, additional yes/no response training)
Number of subjects: 13
Study 14555365 — intervention group
Group type: COMPARATOR
Intervention: Treatment B (standard hospital environment and interventions)
Number of subjects: 13
Study 11099571 — intervention group
Group type: EXPERIMENTAL
Intervention: Written oral hygiene instruction
Number of subjects: 65
Study 11099571 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape oral hygiene instruction
Number of subjects: 65
Study 11099571 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one instruction by a hygienist
Number of subjects: 65
Study 8881789 — intervention group
Group type: EXPERIMENTAL
Intervention: pH adjusted lignocaine
Number of subjects: 40
Study 8881789 — intervention group
Group type: COMPARATOR
Intervention: commercial lignocaine
Number of subjects: 40
Study 1576626 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef 200 mg once daily for 7 days
Number of subjects: 333
Study 1576626 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg thrice daily for 7 days
Number of subjects: 333
Study 4048810 — intervention group
Group type: COMPARATOR
Intervention: Oral ketoprofen (2 x 50 mg) administered at 7:00 a.m., 1:00 p.m., 7:00 p.m., and 1:00 a.m.
Number of subjects: 16
Study 4048810 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of ketoprofen (5 mg/kg/day) over 24 hours
Number of subjects: 16
Study 31519496 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based decision aid
Number of subjects: 97
Study 31519496 — intervention group
Group type: COMPARATOR
Intervention: Avatar-based decision aid
Number of subjects: 97
Study 28049699 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP <130 mm Hg
Number of subjects: 3035
Study 28049699 — intervention group
Group type: COMPARATOR
Intervention: SBP 130 to <145 mm Hg (reference group)
Number of subjects: 3035
Study 28049699 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP ≥145 mm Hg
Number of subjects: 3035
Study 25218328 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard technique (14 patients)
Number of subjects: 29
Study 25218328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue preservation technique (15 patients)
Number of subjects: 29
Study 24088805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sincronil
Number of subjects: 60
Study 24088805 — intervention group
Group type: EXPERIMENTAL
Intervention: Topamax
Number of subjects: 60
Study 21131307 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonorrhoea dacron‐tipped swab
Number of subjects: 121
Study 21131307 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia rayon‐tipped swab
Number of subjects: 121
Study 21131307 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic 10 μl urethral loop
Number of subjects: 121
Study 21131307 — intervention group
Group type: EXPERIMENTAL
Intervention: First swab (any type)
Number of subjects: 121
Study 21131307 — intervention group
Group type: EXPERIMENTAL
Intervention: Second swab (any type)
Number of subjects: 121
Study 21131307 — intervention group
Group type: EXPERIMENTAL
Intervention: Third swab (any type)
Number of subjects: 121
Study 19131659 — intervention group
Group type: EXPERIMENTAL
Intervention: OCSP syndrome classification
Number of subjects: 510
Study 17195085 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 168
Study 17195085 — intervention group
Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 168
Study 15519449 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertiveness training program (eight 2-hour sessions once a week)
Number of subjects: 69
Study 15519449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study 11226784 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon5 (sodium hyaluronate 2.3%)
Number of subjects: 81
Study 11226784 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat (sodium hyaluronate 3.0%-chondroitin sulfate 4.0%)
Number of subjects: 81
Study 11226784 — intervention group
Group type: EXPERIMENTAL
Intervention: OcuCoat (hydroxypropyl methylcellulose 2.0%)
Number of subjects: 81
Study 11226784 — intervention group
Group type: EXPERIMENTAL
Intervention: Celoftal (hydroxypropyl methylcellulose 2.0%)
Number of subjects: 81
Study 11226784 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon GV (sodium hyaluronate 1.4%)
Number of subjects: 81
Study 9522023 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (therapeutic doses)
Number of subjects: 18
Study 7856290 — intervention group
Group type: EXPERIMENTAL
Intervention: CFA/II in biodegradable polymer microspheres (BPM), 1 mg administered via intestinal tube on days 0, 7, 14, and 28.
Number of subjects: 10
Study 7856290 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated volunteers).
Number of subjects: 10
Study 7856290 — intervention group
Group type: EXPERIMENTAL
Intervention: CFA/II in biodegradable polymer microspheres (BPM).
Number of subjects: 10
Study 2796243 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophyllin treatment (oral, therapeutic range 4-10 micrograms/ml)
Number of subjects: 20
Study 2796243 — intervention group
Group type: COMPARATOR
Intervention: No aminophyllin treatment
Number of subjects: 20
Study 2796243 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 338270 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (n = 15)
Number of subjects: 30
Study 338270 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene (n = 15)
Number of subjects: 30
Study 338270 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol and Thiothixene (combined)
Number of subjects: 30
Study 30988133 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (AT1R receptor antagonist)
Number of subjects: 0
Study 30988133 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (AngII)
Number of subjects: 0
Study 30988133 — intervention group
Group type: EXPERIMENTAL
Intervention: C21 (AT2R-selective agonist)
Number of subjects: 0
Study 26961091 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB)
Number of subjects: 0
Study 26961091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25549193 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral C7 neurotization surgery
Number of subjects: 6
Study 25549193 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation only (Control)
Number of subjects: 6
Study 23830306 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance diet for egg protein intake
Number of subjects: 0
Study 23830306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tolerance induction
Number of subjects: 0
Study 23830306 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE)
Number of subjects: 0
Study 23830306 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0
Study 23830306 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple viral vaccine (MMR)
Number of subjects: 0
Study 22164960 — intervention group
Group type: COMPARATOR
Intervention: Fumaric acid supplementation (0 g/d, 100 g/d, 200 g/d, 300 g/d) with maize silage
Number of subjects: 62
Study 22164960 — intervention group
Group type: COMPARATOR
Intervention: Fumaric acid supplementation (0 g/d, 100 g/d, 200 g/d, 300 g/d) with grass silage
Number of subjects: 62
Study 22164960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumaric acid supplementation (300 g/d)
Number of subjects: 62
Study 22164960 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 g/d fumaric acid)
Number of subjects: 62
Study 22164960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumaric acid supplementation (0 g/d, 300 g/d)
Number of subjects: 62
Study 22164960 — intervention group
Group type: COMPARATOR
Intervention: Silage type (maize vs grass)
Number of subjects: 62
Study 19438778 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpentier‐Edwards Perimount
Number of subjects: 86
Study 19438778 — intervention group
Group type: COMPARATOR
Intervention: SJM Epic
Number of subjects: 86
Study 16776791 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy and physical therapy sessions involving home modifications, problem solving, and training in energy conservation, safe performance, balance, muscle strength, and fall recovery techniques.
Number of subjects: 319
Study 16776791 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 319
Study 16776791 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy and physical therapy intervention
Number of subjects: 319
Study 14702451 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral skills training program
Number of subjects: 31
Study 14702451 — intervention group
Group type: EXPERIMENTAL
Intervention: Eddie Eagle GunSafe Program
Number of subjects: 31
Study 14702451 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 31
Study 11562581 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic pulsatile (n=9, 2.5 L)
Number of subjects: 52
Study 11562581 — intervention group
Group type: COMPARATOR
Intervention: Normothermic pulsatile (n=8, 2.5 L/min/m2)
Number of subjects: 52
Study 11562581 — intervention group
Group type: COMPARATOR
Intervention: Normothermic nonpulsatile (n=12, 2.5 L)
Number of subjects: 52
Study 11562581 — intervention group
Group type: COMPARATOR
Intervention: Normothermic nonpulsatile (n=12, 2.8 L)
Number of subjects: 52
Study 11562581 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic nonpulsatile (n=11, 2.5 L)
Number of subjects: 52
Study 9158469 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 198
Study 9158469 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 198
Study 9158469 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 198
Study 8201064 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0
Study 8201064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 0
Study 8201064 — intervention group
Group type: COMPARATOR
Intervention: Standard procedures to maintain pharmacotherapy blinds
Number of subjects: 0
Study 3047304 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulprostone 500 mcg 3 times at 4-hour intervals (regimen 1)
Number of subjects: 12
Study 3047304 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulprostone 500 mcg every 6 hours for up to 6 injections (regimen 2)
Number of subjects: 12
Study 3047304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine fetal death cases treated with regimen 1
Number of subjects: 12
Study 3047304 — intervention group
Group type: EXPERIMENTAL
Intervention: Failures in regimen 1
Number of subjects: 12
Study 3047304 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 12
Study 28952176 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Cryosim‐1 cream applied twice daily for seven days
Number of subjects: 9
Study 28952176 — intervention group
Group type: COMPARATOR
Intervention: Placebo-vehicle cream applied twice daily for seven days
Number of subjects: 9
Study 28952176 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Cryosim‐1 cream
Number of subjects: 9
Study 28952176 — intervention group
Group type: COMPARATOR
Intervention: Placebo-vehicle cream
Number of subjects: 9
Study 28336747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pulse intake
Number of subjects: 325
Study 28336747 — intervention group
Group type: EXPERIMENTAL
Intervention: Available carbohydrate
Number of subjects: 325
Study 28336747 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic load
Number of subjects: 325
Study 28336747 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch
Number of subjects: 325
Study 28336747 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fat intake
Number of subjects: 325
Study 28336747 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat intake
Number of subjects: 325
Study 25676011 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 40
Study 25676011 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study 23288407 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation (Auditory, Tactile, Visual and Vestibular stimulus) for 12 min per session, 5 sessions per week
Number of subjects: 50
Study 23288407 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation
Number of subjects: 50
Study 23288407 — intervention group
Group type: COMPARATOR
Intervention: Routine NICU care
Number of subjects: 50
Study 21905251 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensor strength and standing balance
Number of subjects: 104
Study 21905251 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing balance in the anteroposterior plane
Number of subjects: 104
Study 21905251 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing balance-physical function associations
Number of subjects: 104
Study 18369591 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCM/PALS with ScvO(2) goal-directed therapy
Number of subjects: 102
Study 18369591 — intervention group
Group type: COMPARATOR
Intervention: ACCM/PALS without ScvO(2) goal-directed therapy
Number of subjects: 102
Study 16818864 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 99
Study 16818864 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy
Number of subjects: 99
Study 16818864 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 99
Study 12614309 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 100 mg/day
Number of subjects: 613
Study 12614309 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 200 mg/day
Number of subjects: 613